NCT05895565View on ClinicalTrials.gov

A Multiple Ascending Doses (MAD) Study of PMG1015 in Idiopathic Pulmonary Fibrosis Subjects

PHASE1RecruitingINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

May 19, 2023

Primary Completion Date

December 20, 2024

Study Completion Date

May 27, 2025

Conditions
IPF
Interventions
DRUG

PMG1015

Including 3 dose levels: level 1, level 2 and level 3

DRUG

PMG1015 placebo

Including 2 dose levels corresponding to PMG1015 level 1 and level 2, with no placebo group set for PMG1015 level 3

Trial Locations (7)

100029

RECRUITING

Site 01, Beijing

200030

RECRUITING

Site 02, Shanghai

200433

RECRUITING

Site 05, Shanghai

210008

RECRUITING

Site 04, Nanjing

230000

RECRUITING

Site 07, Hefei

430030

RECRUITING

Site 03, Wuhan

510120

RECRUITING

Site 06, Guangzhou

All Listed Sponsors
lead

Pulmongene Ltd.

INDUSTRY